These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7435389)

  • 21. Some aspects of the clinical pharmacology of intravenous disopyramide after myocardial infarction.
    Hillis WS; Tweddel A; Lorimer AR; Lawrie TD
    J Int Med Res; 1976; 4(1 Suppl):74-7. PubMed ID: 1026533
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of disopyramide on repolarisation and intraventricular conduction in man.
    Endresen K; Amlie JP; Forfang K
    Eur J Clin Pharmacol; 1988; 35(5):467-74. PubMed ID: 2466670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacology of Norpace.
    Dean RR
    Angiology; 1975 Jan; 26(1 Pt 2):67-84. PubMed ID: 1115403
    [No Abstract]   [Full Text] [Related]  

  • 24. Antiarrhythmic and electrophysiologic effects of bepridil in chronically infarcted conscious dogs.
    Lynch JJ; Montgomery DG; Ventura A; Lucchesi BR
    J Pharmacol Exp Ther; 1985 Jul; 234(1):72-80. PubMed ID: 3874285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic ventricular tachyarrhythmias in the conscious dog: prevention by UM-272 (dimethylpropranolol).
    Patterson E; Lucchesi BR
    J Cardiovasc Pharmacol; 1981; 3(4):769-80. PubMed ID: 6167806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lidocaine converts inducible ventricular fibrillation into sustained ventricular tachycardia in conscious dogs with recent myocardial infarction.
    Aidonidis I; Brachmann J; Rizos I; Toutouzas P; Kübler W
    Cardiology; 1994; 85(6):378-87. PubMed ID: 7697673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiarrhythmic, electrophysiologic and hemodynamic effects of ACC-9358.
    Brown BS; Calzadilla SV; Diemer MJ; Hartman JC; Reynolds RD
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1225-34. PubMed ID: 3694532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase.
    Cobbe SM; Hoffman E; Ritzenhoff A; Brachmann J; Kübler W; Senges J
    Circulation; 1983 Oct; 68(4):865-71. PubMed ID: 6616781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disopyramide-induced ventricular tachycardia.
    Lo KS; Gantz KB; Stetson PL; Lucchesi BR; Pitt B
    Arch Intern Med; 1980 Mar; 140(3):413-4. PubMed ID: 6153888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia.
    Vismara LA; Vera Z; Miller RR; Mason DT
    Am J Cardiol; 1977 Jun; 39(7):1027-34. PubMed ID: 326016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemodynamic and electrophysiologic effects of disopyramide enantiomers in a canine blood superfusion model.
    Kidwell GA; Lima JJ; Schaal SF; Muir WW
    J Cardiovasc Pharmacol; 1989 Apr; 13(4):644-55. PubMed ID: 2471004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time-dependent change in electrophysiologic milieu after myocardial infarction in conscious dogs.
    Duff HJ; Martin JM; Rahmberg M
    Circulation; 1988 Jan; 77(1):209-20. PubMed ID: 3335068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-arrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia.
    Hulting J; Rosenhamer G
    J Int Med Res; 1976; 4(1 Suppl):90-5. PubMed ID: 1026537
    [No Abstract]   [Full Text] [Related]  

  • 34. Atypical ventricular tachycardia as a manifestation of disopyramide toxicity.
    Meltzer RS; Robert EW; McMorrow M; Martin RP
    Am J Cardiol; 1978 Dec; 42(6):1049-53. PubMed ID: 727132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical and hemodynamic effects of disopyramide phosphate administered i.v. in cardiopathic subjects (author's transl)].
    Chiariello M; Santinelli V; Ferro G; Tari MG; Stanislao M; Condorelli M
    G Ital Cardiol; 1979; 9(9):975-83. PubMed ID: 520746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of disopyramide on electrophysiologic properties of canine cardiac purkinje fibers.
    Danilo P; Hordof AJ; Rosen MR
    J Pharmacol Exp Ther; 1977 Jun; 201(3):701-10. PubMed ID: 864604
    [No Abstract]   [Full Text] [Related]  

  • 37. Electrophysiologic effects of disopyramide studied in a hypoxic canine Purkinje fiber model.
    Yamada S; Nishimura M; Watanabe Y
    J Electrocardiol; 1982 Jan; 15(1):31-9. PubMed ID: 7069318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of prenylamine and AQ-A 39 on reentrant ventricular arrhythmias induced during the late myocardial infarction period in conscious dogs.
    Aidonidis I; Egel E; Hilbel T; Kuebler W; Brachmann J
    J Cardiovasc Pharmacol; 1993 Sep; 22(3):401-7. PubMed ID: 7504130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effects of disopyramide and quinidine on action potentials of canine ventricular myocardium and Purkinje fibers after myocardial infarction].
    Gao TL; Brachmann J; Senges J
    Zhongguo Yao Li Xue Bao; 1987 May; 8(3):238-42. PubMed ID: 2959020
    [No Abstract]   [Full Text] [Related]  

  • 40. Antiarrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocardial infarction: evaluation using three-dimensional mapping.
    Zuanetti G; Corr PB
    J Pharmacol Exp Ther; 1991 Jan; 256(1):325-34. PubMed ID: 1988663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.